spironolactone has been researched along with malondialdehyde in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, D; Kirimura, K; Miyazaki, M; Muramatsu, M; Sakonjo, H; Takai, S | 1 |
| Bobadilla, NA; Cruz, C; Gamba, G; Mejía-Vilet, JM; Ramírez, V; Uribe, N | 1 |
| Bao, Y; Jia, R; Yuan, J | 1 |
| Chen, Y; Li, L; Pen, JX; Qi, YF; Tang, CS; Wang, X; Wu, SY | 1 |
| Brown, L; Iyer, A; Mesripour, A | 1 |
| Celikel, C; Cetinel, S; Dulger, GA; Imeryuz, N; Kabasakal, L; Kan, B; Orun, O; Toklu, HZ; Yuksel, M | 1 |
| Adel, H; Khalifa, MM; Taye, A | 1 |
| El-Moselhy, MA; Hofni, A; Khalifa, MM; Taye, A | 1 |
8 other study(ies) available for spironolactone and malondialdehyde
| Article | Year |
|---|---|
Eplerenone inhibits atherosclerosis in nonhuman primates.
Topics: Acetylcholine; Animals; Aorta; Atherosclerosis; Carotid Arteries; Chemokine CCL2; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Eplerenone; Lipid Metabolism; Lipoproteins, LDL; Macaca fascicularis; Male; Malondialdehyde; Peptidyl-Dipeptidase A; Renin; Spironolactone; Tunica Intima; Ultrasonography; Vasodilation | 2005 |
Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone.
Topics: Aldosterone; Animals; Blotting, Western; Catalase; Glutathione Peroxidase; Immunohistochemistry; In Situ Nick-End Labeling; Kidney Diseases; Lipid Peroxidation; Male; Malondialdehyde; Mineralocorticoid Receptor Antagonists; Rats; Rats, Wistar; Reperfusion Injury; RNA; Spironolactone; Superoxide Dismutase; Vasoconstriction | 2007 |
Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibronectins; Glutathione Peroxidase; Hypertrophy; Kidney Cortex; Kidney Glomerulus; Male; Malondialdehyde; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Plasminogen Activator Inhibitor 1; Rats; Rats, Sprague-Dawley; RNA, Messenger; Spironolactone; Superoxide Dismutase; Transforming Growth Factor beta1 | 2007 |
[The effect of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on cardiac function in calcium-overload rats].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium; Creatine Kinase; L-Lactate Dehydrogenase; Lipid Peroxidation; Male; Malondialdehyde; Mineralocorticoid Receptor Antagonists; Myocardium; Nicotine; Rats; Rats, Sprague-Dawley; Spironolactone; Vitamin D | 2007 |
Mineralocorticoid receptors mediate cardiac remodelling in morphine-dependent rats.
Topics: Animals; Blood Pressure; Cardiomegaly; Dose-Response Relationship, Drug; Heart; Heart Ventricles; In Vitro Techniques; Male; Malondialdehyde; Microscopy, Confocal; Mineralocorticoid Receptor Antagonists; Morphine; Organ Size; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Spironolactone; Ventricular Remodeling | 2012 |
A study comparing the efficacy of antimicrobial agents versus enzyme (P-gp) inducers in the treatment of 2,4,6 trinitrobenzenesulfonic acid-induced colitis in rats.
Topics: Animals; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Ciprofloxacin; Colitis; Colon; Glutathione; Ileum; Male; Malondialdehyde; NF-kappa B; Peroxidase; Pregnane X Receptor; Rats; Rats, Sprague-Dawley; Receptors, Steroid; Rifampin; Spironolactone; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha | 2013 |
Spironolactone improves endothelial dysfunction in streptozotocin-induced diabetic rats.
Topics: Administration, Oral; Animals; Antioxidants; Aorta; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelium, Vascular; Male; Malondialdehyde; Mineralocorticoid Receptor Antagonists; Nitric Oxide; Nitric Oxide Synthase Type III; Rats; Rats, Wistar; Spironolactone; Streptozocin | 2014 |
Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
Topics: Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Therapy, Combination; Inflammation; Kidney; Male; Malondialdehyde; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Oxidative Stress; Protective Agents; Rats; Rats, Wistar; Spironolactone; Streptozocin; Superoxides; Tetrazoles; Transforming Growth Factor beta | 2014 |